Strides' subsidiary given approval for Acteazolamide tablets
22 November 2017 -

The US Food and Drug Administration (FDA) has granted approval to Indian pharmaceutical company Strides' wholly-owned subsidiary Shasun for its Acteazolamide tablets, the company said on Wednesday.

The US health regulator has approved Acteazolamide tablets to be used to prevent and reduce the symptoms of altitude sickness.

In a BSE filing, the company said that the product was a generic version of Diamox tablets.

It has been indicated in the dosages of 125 mg and 250 mg. Strides said the product, to be launched immediately, will be marketed by Strides Pharma Inc in the US.

According to IMS sales data, the US market for Acteazolamide tablets is worth approximately USD53m.